Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients

Παρόμοια τεκμήρια

• The rainbow cohort: 96 week follow-up of saquinavir-containing regimens in previously antiretroviral therapy (ART)-naïve and pre-treated but protease inhibitor (PI)- naïve hiv-infected patients
  ανά: Knechten, H, κ.ά.
  Έκδοση: (2011)
• Safety and Efficacy in HIV-1-Infected Patients Treated with Ritonavir-Boosted Saquinavir Mesylate
  ανά: Knechten, Heribert, κ.ά.
  Έκδοση: (2010)
• Pharmacokinetics of Saquinavir, Atazanavir, and Ritonavir in a Twice-Daily Boosted Double-Protease Inhibitor Regimen
  ανά: von Hentig, Nils, κ.ά.
  Έκδοση: (2007)
• The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?
  ανά: Wiesmann, Frank, κ.ά.
  Έκδοση: (2011)
• Synergistic Interactions of the Antiretroviral Protease Inhibitors Saquinavir and Ritonavir with Chloroquine and Mefloquine against Plasmodium falciparum In Vitro
  ανά: Skinner-Adams, T. S., κ.ά.
  Έκδοση: (2007)